

Fig. 1





Fig. 2



Neutralization of TNF Cytotoxicity by Murine A2







FIG. 3





06 630

Fig. 6








Fig 8




pA2HG1apgpt



pA2HuKapgpt

Murine A2 ELISA with chimeric A2 competitor



Chimeric A2 ELISA with murine A2 competitor




FIG. 9

Scatchard Analysis of I-125 mA2 and cA2 IgG





Fig. 10

Neutralization of TNF Cytotoxicity by Chimeric A2




FIG. 11

Neutralization of ELAM-1 Expression by Chimeric A2




FIG. 12

Figure 13

SEQUENCE OF HUMAN TNF

[illegible]

Figure 14





Figure 15

PEPTIDE SEQUENCE OF HUMAN TNF RECOGNIZED BY cA2

1 Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
10
21 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly
30
41 Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile
50
61 Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile
70
81 Ser Arg Ile Ala Val Ser Thr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
90
101 Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu
110
121 Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp
130
141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
150

Figure 16



87 943852

Figure 17A

CA2 LIGHT CHAIN VARIABLE REGION SEQUENCE

GACATCTTCCTGACTCAGTCTCCAGCCATCCTGTCTGTCAGTCCAGCACAAAGAGTCACT
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer

TTCTCCTCCACGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGGTATCAGCAAAGAACA
PheSerCysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr

AATCGTTTCCTCAAGGCTTCTCATAAACTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC
AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGGTTTAGTGGCAGTCCATCAGCCACACATTTTACTCTTAGCATCAACACTCTCCACTCT
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer

GAAGATATTGCAGATTATTACTGTCAAGAAAGTCATACCTCCCCATTACCTTCCCTCC
GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

GGGACAAATTTGGAAGTAAAA
GlyThrAsnLeuGluValLys

CAACTCAACCTTCACCACTCTCCACCACCCTTCCTCCAACCTCCACGATCCATCAAACTC
GluValLysLeuGluGluSerGlyGlyGlyLeuValGlnProGlyGlySerMetLysLeu

TCCTGTGTTCCTCTGGATTCATTTTCAGTAACCACTGGATGAACTGGGTCCGCCAGTCT
SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer

CCAGAGAAGGGGCTTGAGTGGGTTCCTCAAATTACATCAAAATCTATTAATTCTGCAAGA
ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr

CATTATGCGGAGTCTGTGAAAGGGAGGTTCCACCATCTCAAGAGATGATTCCAAAAGTCT
HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla

GTCTACCTGCAAATGACCGACTTAAGAACTGAAGACACTGGCGTTTATTACTGTTCAGG
ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg

AATTACTACGGTAGTACCTACGACTACTCCCGCCAAGCCACCACTCTCACAGTCTCC
AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer

Figure 17B

anti-TNF Trial

EMS




FIG-18

anti-TNF Trial

Pain





FIG. 19

anti-TNF Trial

Ritchie Articular Index



anti-TNF Trial

Swollen Joints




FIG 21

anti-TNF Trial

CRP




FIG. 22

anti-TNF Trial

ESR




FIG 23

anti-TNF Trial

Index of Disease Activity




FIG 24